Product information and disease descriptionPlace of product in therapyDisease description
Definition and etiology
6 evidence topics · 6 sources
Definition of castration-resistant prostate cancer
Castrate testosterone threshold in clinical trials
“PCWG3 retains the definition of castrate as ≤ 50 ng/dL of testosterone (or ≤ 0.50 ng/mL or 1.73 nmol/L) but encourages investigators to consider using ultrasensitive testosterone assays with a sensitivity to 1 to 2 ng/dL when evaluating a drug known or suspected to change androgen levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical states model and lines of prior therapy
“Considers mCRPC in terms of number of lines of prior therapy rather than in relation to docetaxel treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“replacing the pre- versus postchemotherapy distinction with a dynamic classification that considers the lines of therapy a patient has received independent of the mechanism of action, the order in which they were administered, and the sensitivity of the tumor to each” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology of castration resistance: continued androgen receptor signaling
“It is now accepted that castration-resistant prostate cancer is not androgen-independent and continues to rely on androgen signaling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An abundance of data acquired since then, however, has made it overwhelmingly clear that residual androgens remaining after castration and AR itself remain central both to the progression to CRPC and to its continued growth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression from prostate cancer to castration resistance
“Together, the data indicate that 10-20% of prostate cancer patients develop CRPC within approximately 5 years of follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Together, ≥ 84% were shown to have metastases at diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote